These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 10999484)

  • 21. (S)-(-)-4-[4-[2-(isochroman-1-yl)ethyl]-piperazin-1-yl] benzenesulfonamide, a selective dopamine D4 antagonist.
    TenBrink RE; Bergh CL; Duncan JN; Harris DW; Huff RM; Lahti RA; Lawson CF; Lutzke BS; Martin IJ; Rees SA; Schlachter SK; Sih JC; Smith MW
    J Med Chem; 1996 Jun; 39(13):2435-7. PubMed ID: 8691438
    [No Abstract]   [Full Text] [Related]  

  • 22. Synthesis and activity of 2-[4-(4-[3H]-2-cyanophenyl)piperazinyl]-N-(2,4,6-[3H]3-3-methylphenyl)acetamide: a selective dopamine D4 receptor agonist and radioligand.
    Matulenko MA; Surber B; Fan L; Kolasa T; Nakane M; Terranova MA; Uchic ME; Miller LN; Chang R; Donnelly-Roberts DL; Namovic MT; Moreland RB; Brioni JD; Stewart AO
    Bioorg Med Chem Lett; 2004 Oct; 14(20):5095-8. PubMed ID: 15380206
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Functional coupling of human D2, D3, and D4 dopamine receptors in HEK293 cells.
    McAllister G; Knowles MR; Ward-Booth SM; Sinclair HA; Patel S; Marwood R; Emms F; Patel S; Smith A; Seabrook GR
    J Recept Signal Transduct Res; 1995; 15(1-4):267-81. PubMed ID: 8903944
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A new arylpiperazine antipsychotic with high D2/D3/5-HT1A/alpha 1A-adrenergic affinity and a low potential for extrapyramidal effects.
    Reitz AB; Bennett DJ; Blum PS; Codd EE; Maryanoff CA; Ortegon ME; Renzi MJ; Scott MK; Shank RP; Vaught JL
    J Med Chem; 1994 Apr; 37(8):1060-2. PubMed ID: 7909336
    [No Abstract]   [Full Text] [Related]  

  • 25. 7-(4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-2(1H)-quinolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity.
    Kikuchi T; Tottori K; Uwahodo Y; Hirose T; Miwa T; Oshiro Y; Morita S
    J Pharmacol Exp Ther; 1995 Jul; 274(1):329-36. PubMed ID: 7616416
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Use of [3H]-clozapine as a ligand of the dopamine D4 receptor subtype in peripheral tissues.
    Ricci A; Bronzetti E; Rossodivita I; Amenta F
    J Auton Pharmacol; 1997 Aug; 17(4):261-7. PubMed ID: 9373785
    [TBL] [Abstract][Full Text] [Related]  

  • 27. trans-1-[(2-Phenylcyclopropyl)methyl]-4-arylpiperazines: mixed dopamine D(2)/D(4) receptor antagonists as potential antipsychotic agents.
    Zhang X; Hodgetts K; Rachwal S; Zhao H; Wasley JW; Craven K; Brodbeck R; Kieltyka A; Hoffman D; Bacolod MD; Girard B; Tran J; Thurkauf A
    J Med Chem; 2000 Oct; 43(21):3923-32. PubMed ID: 11052797
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dopamine receptor sequences. Therapeutic levels of neuroleptics occupy D2 receptors, clozapine occupies D4.
    Seeman P
    Neuropsychopharmacology; 1992 Dec; 7(4):261-84. PubMed ID: 1362057
    [TBL] [Abstract][Full Text] [Related]  

  • 29. (Aryloxy)alkylamines as selective human dopamine D4 receptor antagonists: potential antipsychotic agents.
    Unangst PC; Capiris T; Connor DT; Doubleday R; Heffner TG; MacKenzie RG; Miller SR; Pugsley TA; Wise LD
    J Med Chem; 1997 Dec; 40(25):4026-9. PubMed ID: 9406594
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characterization of [3H]clozapine binding sites in rat brain.
    Kusumi I; Matsubara S; Takahashi Y; Ishikane T; Koyama T
    J Neural Transm Gen Sect; 1995; 101(1-3):51-64. PubMed ID: 8695057
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Aripiprazole's low intrinsic activities at human dopamine D2L and D2S receptors render it a unique antipsychotic.
    Tadori Y; Miwa T; Tottori K; Burris KD; Stark A; Mori T; Kikuchi T
    Eur J Pharmacol; 2005 May; 515(1-3):10-9. PubMed ID: 15894311
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Enhanced D1 affinity in a series of piperazine ring substituted 1-piperazino-3-arylindans with potential atypical antipsychotic activity.
    Bøgesø KP; Arnt J; Frederiksen K; Hansen HO; Hyttel J; Pedersen H
    J Med Chem; 1995 Oct; 38(22):4380-92. PubMed ID: 7473566
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor.
    Jordan S; Koprivica V; Chen R; Tottori K; Kikuchi T; Altar CA
    Eur J Pharmacol; 2002 Apr; 441(3):137-40. PubMed ID: 12063084
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vitro pharmacology of aripiprazole, its metabolite and experimental dopamine partial agonists at human dopamine D2 and D3 receptors.
    Tadori Y; Forbes RA; McQuade RD; Kikuchi T
    Eur J Pharmacol; 2011 Oct; 668(3):355-65. PubMed ID: 21816144
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cyclic benzamides as mixed dopamine D2/serotonin 5-HT2 receptor antagonists: potential atypical antipsychotic agents.
    Norman MH; Rigdon GC; Navas F; Cooper BR
    J Med Chem; 1994 Aug; 37(16):2552-63. PubMed ID: 7914539
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Syntheses and properties of the major hydroxy metabolites in humans of blonanserin AD-5423, a novel antipsychotic agent.
    Ochi T; Sakamoto M; Minamida A; Suzuki K; Ueda T; Une T; Toda H; Matsumoto K; Terauchi Y
    Bioorg Med Chem Lett; 2005 Feb; 15(4):1055-9. PubMed ID: 15686911
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New arylpiperazinylalkyl derivatives of 8-alkoxy-purine-2,6-dione and dihydro[1,3]oxazolo[2,3-f]purinedione targeting the serotonin 5-HT1A /5-HT2A /5-HT7 and dopamine D2 receptors.
    Chłoń-Rzepa G; Zagórska A; Bucki A; Kołaczkowski M; Pawłowski M; Satała G; Bojarski AJ; Partyka A; Wesołowska A; Pękala E; Słoczyńska K
    Arch Pharm (Weinheim); 2015 Apr; 348(4):242-53. PubMed ID: 25773907
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Structure-activity relationships of a series of substituted benzamides: potent D2/5-HT2 antagonists and 5-HT1a agonists as neuroleptic agents.
    Norman MH; Rigdon GC; Hall WR; Navas F
    J Med Chem; 1996 Mar; 39(5):1172-88. PubMed ID: 8676355
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phenylpiperazinylmethylheterocycle derivatives: synthesis and dopamine receptor binding profiles.
    Abadi AH
    Arch Pharm (Weinheim); 2004 Jul; 337(7):383-90. PubMed ID: 15237388
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dopamine D3 and D4 receptor antagonists: synthesis and structure--activity relationships of (S)-(+)-N-(1-Benzyl-3-pyrrolidinyl)-5-chloro-4- [(cyclopropylcarbonyl) amino]-2-methoxybenzamide (YM-43611) and related compounds.
    Ohmori J; Maeno K; Hidaka K; Nakato K; Matsumoto M; Tada S; Hattori H; Sakamoto S; Tsukamoto S; Usuda S; Mase T
    J Med Chem; 1996 Jul; 39(14):2764-72. PubMed ID: 8709107
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.